T17249 |
VZ185
|
2306193-61-1
|
98%
|
|
VZ185 is an effective and selective dual BRD7/9 PROTAC degrader (DC50s: 4.5 and 1.8 nM, respectively).
|
T11292 |
FKBP12 PROTAC dTAG-7
|
2064175-32-0
|
98%
|
|
FKBP12 PROTAC dTAG-7 (dTAG-7) is a heterobifunctional compound that selectively degrades the BET bromodomain transcriptional co-activator BRD4 by connecting BET ...
|
T77680 |
BRD7-IN-3
|
|
98%
|
|
BRD7-IN-3 (compound 1-78) functions as a dual inhibitor targeting the bromodomain-containing proteins BRD7 and BRD9, demonstrating half-maximal inhibitory concen...
|
T77975 |
PROTAC BRD9 Degrader-6
|
2676211-62-2
|
98%
|
|
PROTAC BRD9 Degrader-6, with an IC50 value of 0.13 nM, is a potent degrader of BRD9 suitable for research on BAF complex-related disorders [1].
|
T78142 |
DC-BPi-11 hydrochloride
|
|
98%
|
|
DC-BPi-11 hydrochloride is a BPTF (bromodomain PHD finger transcription factor) inhibitor with an IC50 value of 698 nM, demonstrating significant anti-proliferat...
|
T78151 |
Bleximenib oxalate
|
2866179-95-3
|
98%
|
|
Menin-MLL Inhibitor 24 (compound A) oxalate, a menin-mixed-lineage leukemia 1 (menin-MLL) inhibitor, is utilized in cancer research [1].
|
T78202 |
IV-255
|
|
98%
|
|
IV-255 is a selective small molecule inhibitor of the BRG1 bromodomain, heightening DNA damage when administered with Temozolomide and Bleomycin. It also curtail...
|
T15419 |
GS-626510
|
1637770-13-8
|
98%
|
|
GS-626510 is an orally bioavailable inhibitor of BET family bromodomains (Kd: 0.59-3.2 nM for BRD2/3/4; IC50: 83 nM and 78 nM for BD1 and BD2).
|
T78660 |
(S,R)-CFT8634
|
2704617-95-6
|
98%
|
|
(S,R)-CFT8634 is a selective and orally active BRD9 protein degrader with potential for researching BRD9-mediated disorders, such as abnormal cellular proliferat...
|
T78682 |
SJ1461
|
2924546-70-1
|
98%
|
|
SJ1461 is a potent, orally active inhibitor of the BET family, selectively targeting and inhibiting BRD2 (BD1), BRD2 (BD2), BRD4 (BD1), and BRD4 (BD2) with respe...
|
T78801 |
BRD7-IN-2
|
|
98%
|
|
BRD7-IN-2 (compound 2-77) is a potent selective inhibitor of bromodomain-containing protein 7 (BRD7), exhibiting significant anti-proliferative activity in prost...
|
T78851 |
BRD4 Inhibitor-28
|
2468960-80-5
|
98%
|
|
BRD4 Inhibitor-28 (Compound 18), an orally active molecule, selectively inhibits the bromodomains of BRD4 (BRD4-BD1 and BRD4-BD2) with IC50 values of 15 and 55 n...
|
T78923 |
DDO-8926
|
|
98%
|
|
DDO-8926 is a potent, selective BET inhibitor shown to markedly diminish mechanical hypersensitivity in neuropathic pain research by suppressing pro-inflammatory...
|
T78933 |
BD-9136
|
|
98%
|
|
BD-9136, a highly selective BRD4 degrader, demonstrates the capability to inhibit tumor growth without inducing adverse effects in mice, showing potential for ca...
|
T78956 |
PROTAC BRD3/BRD4-L degrader-2
|
|
98%
|
|
PROTAC BRD3/BRD4-L degrader-2, a PROTAC molecule, selectively degrades cellular BRD3 and BRD4-L with K i values of 16.91 and 2.8 nM, respectively, and exhibits r...
|
T78989 |
BET-IN-16
|
2089390-09-8
|
98%
|
|
BET-IN-16 (Comp I), a bromodomain and extra-terminal (BET) inhibitor, demonstrates anticancer activity by impeding the growth of prostate cancer cells. It exhibi...
|
T79016 |
BET-IN-14
|
2243669-93-2
|
98%
|
|
BET-IN-14 is a pan BET inhibitor with an IC50 of 5.35 nM, demonstrating oral activity and anticancer properties [1].
|
T79017 |
GSK737
|
2748687-95-6
|
98%
|
|
GSK737 is a dual inhibitor of BRD4 BD1 and BD2, exhibiting pIC50 values of 5.3 and 7.3, respectively. It demonstrates low clearance, along with favorable solubil...
|
T79018 |
GSK217
|
2748687-92-3
|
98%
|
|
GSK217 is a potent and selective inhibitor of the bromo and extraterminal domain (BET) second bromodomain (BD2) with high solubility, utilized in oncology and im...
|
T79034 |
GXF-111
|
|
98%
|
|
GXF-111, a proteolysis targeting chimera (PROTAC) molecule, efficiently induces the selective degradation of the BRD3 and BRD4-L proteins. It exhibits high bindi...
|